At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 103 enrolled
Drug / intervention
Norditropin NordiFlex®device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of the Ease of Use of Norditropin NordiFlex® Relative to the One of the Device Previously Used by Patients or Parents
In Brief
A Phase 4 clinical trial evaluating Norditropin NordiFlex® for Growth Hormone Disorder and 8 related conditions. Completed, enrolled 103 participants across 1 site.
Detailed Summary
This study is conducted in Europe. The aim of this study is to compare the easiness of use of Norditropin NordiFlex® device to the device previously used by patients or parents.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGrowth Hormone Disorder, Growth Hormone Deficiency in Children, Foetal Growth Problem, Small for Gestational Age, Genetic Disorder, Turner Syndrome, Chronic Kidney Disease, Chronic Renal Insufficiency, Delivery Systems
CountriesFrance
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedNov 2010
Primary CompletionApr 2011
TodayJul 2026
First PostedNov 22, 2010
Enrollment StartNov 1, 2010
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.6 years ago
Interventions
Norditropin NordiFlex®device
Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice